Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Andrew McConaghie

Senior Writer

Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.

He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.

Latest From Andrew McConaghie

Progress In Pharma’s Slow Battle Against Respiratory Syncytial Virus

Pfizer is up against AstraZeneca and Sanofi in developing competing approaches to tackling the unmet need in respiratory syncytial virus (RSV). But earlier failures mean all players will need much more data to sway regulators.

Commercial Clinical Trials

US Studies Hold The Key To COVID-19 Vaccines Race

US demands for 30,000 subject studies and harmonized protocols mean a robust result could arrive soon – but recruitment could still be a challenge.  

Commercial Companies

Sanofi Forecasts Strong Flu Vaccine Growth, Accelerates COVID Plans

While Dupixent and oncology provide the backbone for future growth, Sanofi could seize an opportunity to expand its vaccines business greatly.

Vaccines Coronavirus COVID-19

Sanofi Impacted By COVID 19 Headwinds, But Dupixent Powers Forward

Company keeps on track on for 2020 earnings target despite pandemic's hit to general medicines and vaccines sales.

Sales & Earnings Coronavirus COVID-19

EU Takes Over COVID-19 Vaccine Negotiations, But Lags Behind US

A quartet of EU countries started vaccine procurement talks with AstraZeneca, but are now allowing the European Commission to take over negotiations.

Coronavirus COVID-19 Europe

Can An Antibody Cocktail Block COVID-19 Infection? Regeneron’s Warp Speed Research Aims To Find Out Soon

The only non-vaccine project backed by Operation Warp Speed, Regeneron’s antibody cocktail could play a crucial role in the fight against SARS-CoV2 – if it works. Clinical development chief David Weinreich talks to Scrip about its innovative adaptive trial collaboration, and how it could provide answers in a matter of months.

Clinical Trials Companies
See All
UsernamePublicRestriction

Register